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About one-third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes.
In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients.
Current therapeutics for NRAS–driven malignancies barely affect overall survival. To date, pathway interference
downstream of mutant NRAS seems to be the most promising approach. In this study, data revealed that mutant
NRAS induced Polo-like kinase 1 (Plk1) expression, and pharmacologic inhibition of Plk1 stabilized the size of
NRAS mutant melanoma xenografts. The combination of mitogen-activated protein kinase/extracellular signal–
regulated kinase kinase (MEK) and Plk1 inhibitors resulted in a signiﬁcant growth reduction of NRAS mutant
melanoma cells in vitro, and regression of xenografted NRAS mutant melanoma in vivo. Independent cell cycle
arrest and increased induction of apoptosis underlies the synergistic effect of this combination. Data further
suggest that the p53 signaling pathway is of key importance to the observed therapeutic efﬁcacy. This study
provides in vitro, in vivo, and ﬁrst mechanistic data that an MEK/Plk1 inhibitor combination might be a promising
treatment approach for patients with NRAS–driven melanoma. As mutant NRAS signaling is similar across
different malignancies, this inhibitor combination could also offer a previously unreported treatment modality
for NRAS mutant tumors of other cell origins.
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INTRODUCTION
Mutations in the neuroblastoma rat sarcoma viral oncogene
homolog (NRAS) gene account for up to 20% of driving
oncogenes in melanoma, making NRAS an enticing target
for treatment (Jakob et al., 2012; Fedorenko et al., 2013).
Although small-molecule inhibitors directed against the
constitutively active protein would be ideal, selectively
targeting mutant RAS in vivo has thus far proven to be
impossible (Eskandarpour et al., 2005; Jaiswal et al., 2009;
Kelleher and McArthur, 2012). Current therapeutics barely
affect overall survival, emphasizing the need for improved
treatment modalities.
Recent advances in the treatment of NRAS mutant
melanoma arise from interfering with key downstream
signaling cascades of RAS, such as the mitogen-activated
protein kinase (MAPK), phosphatidylinositol 3 kinase, and Ral
pathways, as well as cell cycle regulator proteins. The MAPK
pathway is critical for anchorage-independent growth and
survival of melanoma cells (Mishra et al., 2010; Ateﬁ et al.,
2011; Greger et al., 2012; Posch et al., 2013; Rebecca et al.,
2014). Nevertheless, single inhibitor treatment, targeting this
pathway, only marginally improved overall survival (Ascierto
et al., 2013). MAPK reactivation and increased signaling
through other prosurvival cascades such as the phos-
phatidylinositol 3 kinase/mammalian target of rapamycin
and/or cell cycle pathways cause resistance to treatment
after only months of therapy (Catalanotti et al., 2013; Long
et al., 2014). Accordingly, current research focuses on the
development of effective inhibitor combinations (Kwong et al.,
2012; Posch et al., 2013).
In this study, we show that the expression of the mitotic
regulator, Polo-like kinase 1 (Plk1), is increased in a large
panel of NRAS mutant melanoma cells. It has been
established previously that Plk1 directly contributes to
malignant transformation and is overexpressed in various
cancers, including melanoma (Wolf et al., 1997; Knecht et al.,
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1999; Gray et al., 2004; Jalili et al., 2011). Nevertheless, Plk1
inhibition alone did not meet preclinical expectations in
recent clinical trials (Lin et al., 2014; Stadler et al., 2014).
The induction of Plk1 by mutant NRAS and the importance
of the MAPK pathway for tumor cell homeostasis provided the
rationale to investigate the combination of an MAPK/ERK
(extracellular signal–regulated kinase) kinase (MEK) inhibitor
(MEKi) and a Plk1 inhibitor (Plk1i) for the treatment of NRAS
mutant melanoma. This study provides the ﬁrst evidence that
combined MEKi and Plk1i treatment induces apoptosis and
synergistically inhibits NRAS mutant melanoma in vitro and
in vivo.
RESULTS
Plk1 is overexpressed in melanoma cells bearing NRAS(Q61)
mutations
To study Plk1 mRNA expression in melanoma, we performed
real-time quantitative PCR in 23 human melanoma cell
lines bearing the most common melanoma driving mutations.
Cell lines are known to harbor mutations in v-Raf murine
sarcoma viral oncogene homolog B (BRAF), NRAS, C-KIT,
and GNAQ/GNA11 (guanine nucleotide-binding protein G(q)
subunit alpha/11). One cell line was wild type for the
above-mentioned mutations. We found Plk1 expression in all
23 cell lines. On average, NRAS mutant cell lines expressed
high levels of Plk1 mRNA, particularly compared with
BRAF mutant melanoma cells (Figure 1a). C-KIT, GNAQ
and GNA11 mutant melanoma cell lines also displayed
increased Plk1 levels compared with BRAF lines tested
(Supplementary Table S1 online). To investigate a potential
correlation between NRAS mutations and Plk1 expression
levels, we stably transduced primary human melanocytes
(PHMs) with different NRAS vectors. PHMs bearing an NRAS
(Q61) mutation showed signiﬁcantly increased Plk1 mRNA
and protein levels compared with PHMs transduced with
NRAS(G12), non-mutagenic NRAS(N24), or empty vector
controls (E) (Figure 1b).
Small-molecule inhibitors of Plk1 and MEK reduce growth of
NRAS mutant melanoma cell lines in vitro
In this study, we used JTP-74057 (trametinib) for selective
MEK inhibition and BI6727 (volasertib) for selective Plk1
inhibition. BI6727 has previously been shown to be a highly
potent and selective inhibitor of Plk1 (IC50= 0.87 nM),
whereas failing to show any inhibitory activity in a panel of
450 kinases up to a drug concentration of 10 μM (Rudolph
et al, 2009). Both inhibitors have previously been
demonstrated to be more potent compared with several other
small-molecule compounds currently available for selective
inhibition of the desired targets (Schmit et al., 2009; Posch
et al., 2013). Inhibitor concentrations to reach 50% growth
inhibition (GI50) varied across cell lines (Figure 2 and
Supplementary Figure S1 online), with several cells displaying
GI50 in the low nanomolar range. All NRAS mutant cells,
except WM1366, required higher concentrations of the Plk1i
compared with the MEKi for equipotent growth inhibition
(Figure 2, Supplementary Figure S1, and Supplementary Table
S2 online). WM3629 cells had a mutation in the Plk1 gene at
633(C4T) (Supplementary Table S1 online). However,
WM3629 cells showed a decrease in cell viability after Plk1
inhibition comparable to Plk1 wild-type cells.
Signaling changes following inhibitor treatment were
examined by a custom mRNA array and immunoblotting
(Figure 3). Plk1 inhibition affected several genes involved in
the cell cycle regulation, with a reduction of E2F1, CDC25A,
CCNE1, and RB1 expression observed after 24 hours of
incubation. The MEKi reduced several cell cycle–related
genes and induced mRNA levels of CEBPD, which has been
reported to be involved in cell cycle regulation and
programmed cell death (Balamurugan and Sterneck, 2013).
We observed an increase ofMAPK1 andMAPK3mRNA levels
by the MEKi (Figure 3a) and elevated mRNA levels of BCL2L1,
an inhibitor of cell death. Immunoblot analyses showed
comparable regulation in select targets at the protein level
(Supplementary Figure S2 online). In addition, we found
reduced phospho (p)-S6 and extinguished p-ERK protein levels
after MEKi treatment. p-AKT was induced in Sk-Mel-2 cells
after MEKi treatment, as described previously (Posch et al.,
2013). Plk1 inhibition resulted in a modest to pronounced
increase of CCNB1 protein levels in Sk-Mel-2 and D04 cells,
respectively (Figure 3a and b).
Pharmacologic targeting of MEK and Plk1 synergistically inhibits
NRAS mutant melanoma cells
Whereas the effects of single inhibitor treatment on cell
viability varied across cell lines, the combination of an MEKi
and Plk1i potently reduced growth in all 10 human NRAS
melanoma cells tested (Figure 2 and Supplementary Figure S1
online). Several different ratios of the two components were
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Figure 1. Neuroblastoma rat sarcoma viral oncogene homolog (NRAS)
mutant cell lines express high levels of Polo-like kinase 1 (Plk1) mRNA. (a)
Relative expression of Plk1 in 23 human melanoma cell lines. NRAS mutant
melanoma cell lines show higher Plk1 expression compared with non-NRAS
and, in particular, to BRAF(V600) mutant cell lines. (b) Plk1 expression in
stably transduced primary human melanocytes (PHMs) expressing the
indicated NRAS mutations or an empty vector control (E). NRAS(Q61) mutant
cells show a signiﬁcant increase of Plk1 expression on mRNA and protein
level compared with empty vector controls, non-oncogenic NRAS(N24)
mutants, and NRAS(G12) mutant cells. Bars represent the mean relative
expression of Plk1. β-Actin served as an endogenous control (N=3; *Po0.05;
mean± SEM). BRAF, v-Raf murine sarcoma viral oncogene homolog B; ΔΔCT,
deltadelta threshold cycle.
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assayed for synergism. Calculating the combination index,
which indicates whether a certain combination is synergistic,
additive, or antagonistic (Supplementary Table S3 online),
revealed synergistic growth inhibition with several different
ratios in select cell lines; however, all NRAS mutant lines
were synergistically inhibited with a ratio of MEK:Plk1=1:8
(Supplementary Figure S3 online). Non-transformed melano-
cytes, as well as a BRAF mutant cell line, showed no further
decrease in cell viability by the addition of the Plk1i to the
MEKi (Supplementary Figure S4 online). Supplementary Table
S2 online summarizes GI50, combination index values, and
the dose reduction index, which indicates how much the dose
of each drug in a synergistic combination may be reduced at a
given effect level, compared with the doses of each drug alone
(Chou and Talalay, 1984).
Signaling changes owing to combination inhibitor treat-
ment were assessed by a custom mRNA array. Cell cycle–
related genes CCND1, CDC25A, CHEK2, E2F1, AurkB, and
Plk1 were potently reduced after 24 hours of incubation with
the MEK/Plk1 combination. Following 24 hours of incubation
with the MEK/Plk1 combination, induction ofMAPK3 was less
pronounced compared with MEKi treatment alone. Interest-
ingly, when comparing the two time points (6 and 24 hours),
we observed induction ofMDM2 and CDKN1A at 24 hours in
both the MEK and Plk1 treatment groups, which persisted in
the combinational group, suggesting regulation of p53/p21
signaling. In addition, Plk1 inhibition attenuated mRNA levels
of the prosurvival gene BCL2L1 in the combinational therapy
when compared with the observed induction of BCL2L1 after
single MEKi treatment. Furthermore, we observed an earlier
and stronger induction of proapoptotic signals, such as
caspase-3/7, with the MEK/Plk1 combination (Figure 3a
and b, Figure 4a and b, and Supplementary Figure S5 online).
Inhibition of MEK and Plk1 results in independent, dual cell
cycle arrests in a phase-dependent manner
As several cell cycle–related genes were affected by the MEK/
Plk1 combination, we investigated cell cycle proﬁles by ﬂow
cytometry. Sk-Mel-2 cells were incubated with varying doses
of an MEKi, a Plk1i, or DMSO control in both monotherapies
and combination therapies (Figure 4c). In support of our
results showing decreased transcription of cyclin D, we
observed a cell cycle arrest at G0/G1 in both MEKi–treated
groups. In contrast, the Plk1i–treated groups showed a G2/M
arrest. Interestingly, when cells are treated with the MEK/Plk1
combination, they arrest in both G1 and G2/M phases in a
dose-dependent manner (Figure 4c). Protein levels of cyclins
D, E, and B in Sk-Mel-2 cells were similar to the transcript
data, showing reduced, slightly decreased, and increased
expression, respectively (Supplementary Figure S2 online).
Taken together, these data suggest that the drugs are capable
of inducing cell cycle arrest at distinct phases, with a potential
overlap during DNA replication.
To determine whether the induced cell cycle arrest is
dependent on the current phase progression of the cell, we
synchronized Sk-Mel-2 cells in late G1 using a thymidine
block. Analyses revealed that cells treated with MEKi
had an observable release from G1 at 8 hours, but to a lesser
extent compared with that of the control condition
(Figure 4d). In addition, MEKi–treated cells maintained
a larger G1 population compared with the other treatment
groups throughout the duration of the experiment, suggesting
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Figure 2. Dose-dependent reduction of cell viability with inhibitors of mitogen-activated protein kinase/extracellular signal–regulated kinase kinase (MEK) and
Polo-like kinase (Plk1). Dose–response curves of ﬁve neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant melanoma cell lines (WM3629,
WM3670, Sk-Mel-2, MM485, and D04) using inhibitors of MEK, Plk1, or their combination. All cell lines were sensitive to MEK and Plk1 inhibition, as well as the
combination of both inhibitors (GI50= concentration at 50% growth inhibition; N= 3; mean± SD; one unit of inhibitor represents 1 nM of the MEK inhibitor
JTP-74057 and 8 nM for the Plk1 inhibitor BI6727).
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that MEK inhibition is capable of inducing an arrest beyond
the restriction point (Supplementary Figure S6 online). Further
evidence of G1 arrest was seen by comparing the combina-
tion with the Plk1i treatment groups in the 18–24 hours
ranges. Importantly, the progressing population in the
combinational treatment group succumbs to G2/M arrest
induced by the Plk1i.
A second synchronization at G2/M was achieved by using
a thymidine-nocodazole block (Figure 4e). After release, the
control cells progressed through mitosis and returned to a G0/
G1 state at 2–4 hours after synchronization, with a second cell
division cycle occurring in the 18–24 hours range. However,
the Plk1i–treated cells failed to release from mitosis and
maintained a G2/M arrest. On comparing the combinational
group with Plk1i alone at 24 hours after release from G2/M
synchronization, there was a measurable, but not signiﬁcant,
increase in the G1 population in MEK/Plk1–treated cells
(Supplementary Figure S6 online). Altogether, these ﬁndings
point into the direction that cells escaping Plk1i–mediated
arrest maintain sensitivity to MEK inhibition.
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Reduction of cell viability by the MEK/Plk1 combination is most
effective in cells expressing p53
In our study, results of the custom mRNA array revealed
regulation of genes in the p21/p53 pathway when cells were
treated with the MEK/Plk1 combination. After 24 hours,
mRNA levels of the p53 transcriptional targets MDM2 and
CDKN1A were increased in both Sk-Mel-2 and D04 lines
(Figure 3a). Conversely, MM485 cells with no detectable
levels of p-p53 had decreased levels of both transcripts
(Supplementary Figure S7 online). Thus, we studied the role of
the p53 pathway by interfering with p53 itself and via
inhibition of Chk proteins (Figure 5a and b). Short hairpin
RNA (shRNA)–mediated knockdown of p53 in Sk-Mel-2
cells (Sk-Mel-2shRNA(p53)) reduced p53 protein levels
(Supplementary Figure S8 online) and impaired Plk1i–
mediated reduction of cell viability (Figure 5a).
As displayed in Figure 5c and d, MM485 cells did not
express detectable levels of p-p53 protein. In line with the
important role of p53 in Sk-Mel-2 cells, MM485 cells also
showed low sensitivity to single Plk1i treatment (Figure 2).
P53 interference did not affect MEKi–mediated reduction
of cell viability. The efﬁcacy of the MEK/Plk1 combination
was also impaired by shRNA–mediated p53 knockdown
(Figure 5a). This effect is, at least partly, a result of reduced
Plk1i–mediated inhibition of cell viability.
Because of the critical role of p53 in the DNA damage
response and its known activation by the checkpoint proteins
Chk1 and Chk2, we investigated the effect of MEKi and Plk1i
on cell viability in the presence of the Chk1/2 inhibitor
PF-0477736 (Chk1/2i). Sk-Mel-2 cells treated with MEKi and
Plk1i individually or in combination demonstrated a biphasic
response to increasing Chk1/2i concentrations (Figure 5b).
This pattern could be the result of Chki being sufﬁcient to
mitigate checkpoint activation induced by Plk1i and, to a
lesser extent, by MEKi in the low micromolar ranges, whereas
higher concentrations result in increased genotoxicity and the
complete abrogation of the DNA damage checkpoints. This
hypothesis is supported by reports showing that Plk1 is
involved in checkpoint adaptation, with DNA damage
checkpoint inhibition, resulting in the sensitization of cancer
cells to DNA-damaging agents (Yoo et al., 2004; Jiang et al.,
2009; Anderson et al., 2011). In support of a Chki-speciﬁc
effect, we were unable to recapitulate these results using other
kinase inhibitors, such as CDK4i or receptor tyrosine kinase
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inhibitors added to the MEK/Plk1 combination (data not
shown).
The MEK/Plk1i combination regresses human NRAS mutant
melanoma xenografts
To test whether the combination of an MEKi and a Plk1i is
also effective in vivo, we established mouse melanoma
xenografts using the human melanoma cell lines Sk-Mel-2
and WM3670. Single drugs or their combination were
administered by oral gavage. The MEKi was given at a dose
of 2 mg kg−1 per day leading to tumor size stabilization, as
demonstrated previously (Posch et al., 2013). The Plk1i was
given three times per week to reach a total amount of
50mg kg− 1 per week and reduced tumor growth. Strikingly,
combined MEK/Plk1 inhibition resulted in signiﬁcant tumor
shrinkage in all cell lines tested (Figure 6a). No side effects of
the combination therapy were observed. Immunoblot ana-
lyses of extracted tumor proteins revealed reduction of p-ERK,
Plk1, p-AKT, and p-RB. We further observed induction of the
proapoptotic proteins BIM and BAX and a reduction of the
antiapoptotic protein Bcl-2, as well as increased caspase-3/7
activity in tumors treated with the combination of MEK/Plk1
(Figure 6b and Supplementary Figure S9 online).
DISCUSSION
It is well established that speciﬁc mutations and deﬁned
signaling aberrations in cancer contribute to differences in the
biological behavior of malignancies. Mutant RAS genes are
found in up to one-third of human cancer (Bos, 1989;
Repasky et al., 2004; Schubbert et al., 2007) with NRAS
mutations being the most prevalent in melanoma (Omerovic
et al., 2007). Therapeutic modalities such as radiation therapy
or chemotherapy for patients with NRAS mutant melanoma
barely affect overall survival. As direct inhibition of mutant
NRAS is at present limited to preclinical models,
pharmacologic interference with important RAS downstream
signaling cascades seems to be the most promising treatment
approach (Kwong et al., 2012; Posch et al., 2013; Vujic et al.,
2014). One of the dominant signaling pathways in NRAS
mutant melanoma is the MAPK pathway. Indeed, inhibition of
the MAPK cascade with the MEKi MEK162 was tested in
patients with NRAS mutant melanoma with encouraging
results. However, responses were short and the development
of resistance was inevitable (Ascierto et al., 2013). This can, at
least in part, be explained by the activation of other
prosurvival pathways such as the phosphatidylinositol 3
kinase/mammalian target of rapamycin pathway after MEK
inhibition (Figure 3) (Posch et al., 2013). Thus, the search for
effective coextinction targets to MAPK inhibition is an
ongoing and important area of research (Kwong et al., 2012;
Ascierto et al., 2013; Posch et al., 2013).
Our data indicate that NRAS(Q61) mutations in PHMs
signiﬁcantly increase Plk1 expression. This observation might
be linked to higher oncogenicity of NRAS(Q61) compared
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Figure 5. (a) P53 signaling affects Polo-like kinase 1 (Plk1) and mitogen-activated protein kinase/extracellular signal–regulated kinase kinase (MEK)/Plk1 inhibitor
efﬁcacy. Stable knockdown of p53 reduced the activity of Plk1 and MEK/Plk1 inhibition. P53 interference had no effect on viability in cells treated with the MEK
inhibitor (MEKi) only, or on vehicle-treated cells. (b) Additional Inhibition of Chk1/2 markedly reduced viability in MEK/Plk1–treated compared with single
inhibitor or vehicle-treated controls in a biphasic manner. (c) Immunoblot analyses of p-p53 and Plk1 in all 10 neuroblastoma rat sarcoma viral oncogene
homolog (NRAS) mutant cell lines used in this study. All cells, except MM485, express p-p53. Plk1 protein expression was pronounced in NRAS(Q61) mutant
cells. (d) Relative expression of the respective proteins compared with β-actin (N=3; mean± SD; SCR= scramble control shRNA; MEKi(JTP-74057)= 20 nM; Plk1
inhibitor (Plk1i)(BI6727)= 100 nM; Chk1/2i=PF-0477736). A.u., arbitrary unit; shRNA, short hairpin RNA.
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with NRAS(G12) mutations in melanocytic cells (Burd et al.,
2014). Comparing Plk1 levels of six NRAS(Q61) with four
NRAS(G12) mutant melanoma cell lines also showed a trend
toward higher Plk1 mRNA and protein expression in NRAS
(Q61) cells; however, these analyses were not statistically
signiﬁcant (P=0.08; P= 0.052; Supplementary Figure S10
online). Hence, we investigated whether the MEKi/Plk1i
combination has antitumor activity in NRAS(G12) and
NRAS(Q61) mutant melanoma cells.
As the discovery of Plk proteins and proof of their biological
importance in cancer maintenance, several compounds have
been developed to target these molecules (Gumireddy et al.,
2005; Liu et al., 2006; Lansing et al., 2007; Steegmaier et al.,
2007; Beria et al., 2010). Among the ﬁve mammalian Plk
family members, selective Plk1 depletion appears to be most
desirable. Plk1 has an important role throughout mitosis by
inﬂuencing the activation of CDK1/cyclin B, centrosome
maturation, spindle formation, kinetochore assembly, and
regulation of microtubule nucleation, as well as chromosome
segregation and execution of cytokinesis (Lane and Nigg,
1996; Seong et al., 2002; Sumara et al., 2004; Van Vugt et al.,
2004; Cholewa et al., 2014). Results presented in this study
suggest that NRAS mutations are linked to high Plk1
expression. This is supported by ﬁndings in a model of
transduced PHMs, as well as in a representative collection of
melanoma lines. In addition, when evaluating clinical data
from The Cancer Genome Atlas of cutaneous melanoma,
mutations in NRAS and increased expression of Plk1 co-occur
(P= 0.009) (Cerami et al., 2012; Gao et al., 2013). Even
though further research is needed to address potential
connections of RAS signaling and Plk1 expression, our
results support current knowledge, highlighting the impor-
tance of Plk1 for viability of RAS–activated malignancies (Luo
et al., 2009; Wang et al., 2013; Yim and Erikson, 2014). Still,
cancer therapy with Plk1is alone is ineffective clinically (Luo
et al., 2009). It is believed that the somewhat low response
rates might be explained by undesired cotargeting of Plk2 and
Plk3, which attenuates the growth inhibitory effects of Plk1
abrogation (Strebhardt, 2010).
In combination with MEK inhibition, however, we observe
signiﬁcant cell death in vitro and tumor shrinkage, as well as
induction of apoptosis in vivo (Figure 6). The importance of cell
cycle regulation in NRAS mutant melanoma has previously
been shown. Recent ﬁndings using MEK/CDK4,6 inhibitor
combinations support this notion, with promising (pre)clinical
results (Kwong et al., 2012). However, several NRAS mutant
cells and clinical tumors do not respond to treatment with
MEK/CDK4,6 inhibitors. This might be explained by recent
ﬁndings suggesting that NRAS mutation status may only
determine response to this combination, when evaluated in
tandem with aberrations in CDKN2A (Dong, 2013). Data
presented in the present study reveal, however, that the MEKi/
Plk1i combination reduces cell growth independent of
CDKN2A and Plk1 mutations (Figure 2, Supplementary
Figure S1 online, and Supplementary Table S1 online).
Mounting evidence suggests that Plk1 affects p53 via direct
binding and subsequent inhibition of its proapoptotic function
(Ando et al., 2004). Accordingly, our ﬁndings show that the
efﬁcacy of Plk1 inhibition is related to p53 expression,
because (i) functional shRNA–mediated knockdown of p53 in
Sk-Mel-2 cells reduced the inhibitory effects of Plk1 and MEK/
Plk1 treatment, and (ii) cells with high p-p53(Ser15) protein
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Figure 6. Tumor size reduction of neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant xenografts with the mitogen-activated protein kinase/
extracellular signal–regulated kinase kinase/Polo-like kinase 1 (MEK/Plk1) combination. (a) Treatment of established mouse xenografts showed tumor size
reduction after initiation of treatment (day 0) with the combination of an MEK inhibitor (MEKi) (2 mg kg− 1 per day) and Plk1 inhibitor (Plk1i) (50 mg kg−1 per
week), but not with either MEKi or Plk1i alone (cell lines: Sk-Mel-2, WM3670; MEKi: JTP-74057; Plk1i: BI6727; n=4). Results are displayed as the mean change
in tumor volume at indicated time points± SD. (b) Corresponding immunoblot analyses of mouse tumors after 3 weeks of treatment with the indicated
conditions.
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expression showed a trend toward requiring less Plk1i to
reach GI50 (Supplementary Figure S11 online) compared with
cells with low or non-detectable p-p53(Ser15) protein
expression (Tsvetkov et al., 2003; Ando et al., 2004;
Strebhardt, 2010).
In addition to RNA silencing of p53, pharmacologic Chk1/2
inhibition also inﬂuenced the efﬁcacy of combined MEK/Plk1
inhibition. However, it should be mentioned that even in cells
with low p53 protein expression MEK/Plk1 treatment effec-
tively reduced cell growth, suggestive of other factors
contributing to the inhibitory activity of this combination.
Although studies investigating the role of Plk1 in p53 signaling
and its function outside of mitosis are scarce (Cholewa et al.,
2013), possible redundancy with p53 family members, p63
and p73, need to be considered. In HeLa cells, p73 is capable
of inducing p21 expression in p53-inactivated cells following
Plk1 inhibition, which results in greater sensitivity to additional
therapeutics (Kreis et al., 2009). Furthermore, it has been
reported that Plk1 phosphorylates and thus suppresses p63
mediated cell death in liver tumor cells (Komatsu et al., 2009).
Taken together, our data offer important insights into the Plk1-
p53 axis, which warrants further investigation.
In addition to the induction of proapoptotic signals in vitro
and in vivo, MEK/Plk1 also caused dual cell cycle arrest. The
MEKi–induced G1 arrest can potentially be attributed to the
reduction in cyclin D expression. Cyclin D is required for cell
cycle re-entry and has previously been shown to be abrogated
in response to MEK inhibition (Modi et al., 2012; Ateﬁ et al.,
2015). Plk1i induces a G2/M arrest through aberrant spindle
pole formation, which ultimately results in mitotic catastrophe
and subsequent apoptosis (Schmit et al., 2009). Results of this
study suggest that cells escaping G1 arrest induced by MEK
inhibition, or cells escaping G2/M arrest resulting from Plk1
inhibition, maintain their susceptibility to the other drug in
combination.
In this study, we provide ﬁrst in vitro and in vivo results
that an MEK/Plk1 combination might be a promising
approach for the treatment of NRAS–driven melanoma. Of
note, and in support of signaling similarities across several
NRAS mutant malignancies (Vujic et al., 2014), this inhibitor
combination also reduced viability in one NRAS mutant
neuroblastoma and one NRAS mutant lung cancer cell line
in vitro (Supplementary Figure S12 online). This is particularly
important, as effective therapeutic modalities for patients with
NRAS mutant tumors of various etiologies are limited.
MATERIALS AND METHODS
Cell culturing, growth inhibition experiments, and immunoblotting
were preformed as described previously (Posch et al., 2013). Detailed
Materials and Methods, as well as information on lentiviral
production, transduction, cell cycle analyses, the custom mRNA
array, and quantitative reverse transcriptase including primer
sequences (Supplementary Table S4 online), can be found in the
electronic supporting information. Delta cycle threshold and
deltadelta cycle threshold values of the custom mRNA array are
provided in Supplementary Table S5. Xenograft studies were
performed in CrTac:NCr-Foxn1nu mice. Inhibitor treatment was
administered by oral gavage when tumors reached a volume of
80–100mm3. All animal studies were approved by IACUC/LARC of
the University of California San Francisco (AN086990).
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